Cagrilintide (5 mg Vial) Dosage Protocol

Supplies Needed

Supply estimates below match the displayed 26-week, once-weekly 4.5 mg target-arm calculation.

• Peptide vials (Cagrilintide, 5 mg each):
  • 26 weeks: 20 vials (98.4 mg calculated total)
• U-100 insulin syringes:
  • One sterile syringe per administration.
  • 26 weeks: 26 syringes
• Bacteriostatic water (10 mL bottles):
  • Use 1.0 mL per vial.
  • 20 vials: 20 mL → 2 bottles
• Alcohol swabs:
  • Two per administration.
  • 26 weeks: 52 swabs - 1 box required (100 swabs each)

Sharps safety: Place used syringes directly into an appropriate sharps container and follow local disposal requirements.

How Cagrilintide Works

Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that participates in appetite and meal-size signaling. Amylin pathways act in brain regions involved in satiation, including the area postrema and other hindbrain networks. These signals can reduce food intake, delay gastric emptying, and alter post-meal glucagon responses.^{[2][3][8][9][10]}

The molecule was engineered with lipid-based modifications that extend exposure compared with native amylin, supporting once-weekly study schedules. Pharmacokinetic research describes a prolonged half-life, although exposure and tolerability can vary across populations and study designs.^[6][7][11] The effect of cagrilintide should therefore be interpreted through the specific trial population, target dose, escalation period, and comparator - not through vial strength alone.

What the Dose-Finding Phase 2 Trial Studied

The placebo-controlled and active-controlled phase 2 trial enrolled adults with overweight or obesity and compared once-weekly cagrilintide target doses of 0.3, 0.6, 1.2, 2.4, and 4.5 mg over 26 weeks. The study used gradual escalation for the higher target-dose groups rather than beginning every participant at the final amount.^[1][4]

Reductions in body weight followed a dose-response pattern. The published estimate for the 4.5 mg group was approximately 10.8% at week 26, compared with approximately 3.0% for placebo. That result describes a group mean from a controlled clinical trial; it does not predict an individual outcome or establish cagrilintide as an approved weight-loss medication.^[4]

The cagrilintide dosage chart on this page uses the 4.5 mg target arm because its four escalation steps can be translated clearly for a 5 mg vial. Other studied target arms stopped at lower doses. The vial strength determines concentration and how many vials are needed - not which research dose is appropriate.

Cagrilintide Alone vs Cagrilintide With Semaglutide

Cagrilintide alone and the co-administered cagrilintide–semaglutide program answer different research questions. Early combination work evaluated the safety, tolerability, pharmacokinetics, and efficacy of co-administered once-weekly cagrilintide with semaglutide.^[6] Later REDEFINE trials studied the fixed combination commonly called CagriSema, including adults with overweight or obesity and a separate population with type 2 diabetes.^[5][12]

Those combination outcomes should not be assigned to cagrilintide alone. Likewise, a cagrilintide dosage with tirzepatide or retatrutide is not established by the single-agent chart on this page. Combination protocols require their own evidence, component calculations, and safety context. Readers looking for the two-component product can use the linked Cagrilintide + Semaglutide blend protocol rather than applying this single-peptide conversion to a blend.

Cagrilintide Weight Loss and Obesity Research

The dose-finding phase 2 trial enrolled people with overweight and obesity and compared cagrilintide 0.3–4.5 mg with placebo and liraglutide. Across the cagrilintide groups, mean weight loss and reductions in body weight generally increased with target dose. The 4.5 mg group showed greater weight loss than placebo at week 26, supporting a dose–response relationship of cagrilintide regarding weight reduction in that clinical trial.^[1][4]

These findings make cagrilintide relevant to obesity management research, but they do not turn the investigational compound into an approved weight loss medication. A group-level mean weight reduction cannot predict sustained weight loss, individual changes in body weight, or whether treatment with cagrilintide is suitable for any person. The evidence is strongest when the study population, comparator, duration, and titration schedule remain explicit.

Later phase 3 trial research evaluated cagrilintide 2.4 mg with semaglutide 2.4 mg. REDEFINE 1 included adults with overweight or obesity, while REDEFINE 2 included adults with type 2 diabetes. The combination with semaglutide produced greater mean weight loss than the individual components in those trials, but combination results must not be presented as the effect of cagrilintide alone.^[5][12]

Safety, Tolerability, and Research Limits

Gastrointestinal events were the most common adverse effects in cagrilintide research. In the phase 2 dose-finding trial, nausea, constipation, diarrhea, and vomiting occurred more often with active study treatment than with placebo, and the frequency varied by dose. Events were generally mild to moderate, but a study-level summary cannot determine individual risk.^[1][4]

Gradual escalation was part of the clinical trial design and is one reason the chart separates each two-week phase. However, the displayed titration schedule remains a research reference only. It should not be read as a personalized instruction, a standard-of-care regimen, or proof that every participant should reach the 4.5 mg target.

• Cagrilintide remains investigational and does not have a routine approved clinical dosage.
• Trial findings apply to defined populations, eligibility criteria, monitoring, and study durations.
• Weight loss outcomes do not establish long-term benefit, individual response, or suitability.
• Combination-study results cannot be substituted for single-agent outcomes.

Subcutaneous Injection Technique in Research Settings

The published cagrilintide studies used subcutaneous administration. General subcutaneous technique includes cleaning the vial stopper and skin, allowing alcohol to dry, placing the needle into subcutaneous tissue, injecting slowly, and rotating sites to reduce repeated local irritation.^[13][14]

• Use a new sterile syringe and needle for every administration.
• Confirm the concentration before translating milligrams into milliliters or U-100 units.
• Rotate among appropriate subcutaneous sites instead of repeatedly using the same location.
• Place used needles immediately into an approved sharps container; never recap or reuse them.

Cagrilintide Dosage Questions

What cagrilintide dose does this chart show?

It shows the escalation used for the 4.5 mg target arm in a phase 2 dose-finding trial: 0.6 mg, 1.2 mg, 2.4 mg, then 4.5 mg once weekly at two-week intervals. The study also included lower target-dose arms.^[1]

How many U-100 units equal 0.6 mg from this 5 mg vial?

With a 1 mL final volume, the concentration is 5 mg/mL. A 0.6 mg amount equals 0.12 mL, or 12 units on a U-100 syringe. This conversion changes if the final volume changes.

How many U-100 units equal 4.5 mg?

At 5 mg/mL, 4.5 mg equals 0.90 mL, or 90 U-100 units. This is a volume conversion from the displayed research arm, not a universal dose recommendation.

Is cagrilintide the same as CagriSema?

No. Cagrilintide is the amylin analogue. CagriSema combines cagrilintide with semaglutide, and its efficacy and safety data come from separate combination trials.^[5][12]

Does a 5 mg vial mean the dose is 5 mg?

No. Five milligrams is the total peptide mass in the vial. The chart’s peptide amount, concentration, syringe units, injection volume, and frequency must be read together.